Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients

Clinical Chemistry

Volumn 51, Issue 1, 2005, Pages 196-201

  Obeid, Rima ^a   Kuhlmann, Martin K ^a,b   Köhler, Hans ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b RENAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; CYSTATHIONINE; FOLIC ACID; HOMOCYSTEINE; METHYLMALONIC ACID; PYRIDOXINE; VITAMIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; REGRESSION ANALYSIS; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; CYSTATHIONINE; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METHYLMALONIC ACID; MIDDLE AGED; RENAL DIALYSIS; VITAMIN B 12; VITAMIN B 6;

EID: 11144278243     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.041210     Document Type: Article

References (35)

1. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
2. Herrmann W, Obeid R, Schorr H, Geisel J. Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk. Clin Chem Lab Med 2003;41:1478-88.
3. Herrmann W, Schorr H, Geisel J, Riegel W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 2001;39:739-46.
4. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-8.
5. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43(Suppl 41):S72-7.
6. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;97:138-41.
7. Samak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
8. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997;17:2554-8.
9. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002;61:609-14.
10. Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003;9:PI19-24.
11. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000;11:1106-16.
12. 12 on homocysteine plasma concentration in hemodialysis patients. Clin Nephrol 2004;61:161-2.
13. Koyama K, Usami T, Takeuchi O, Morozumi K, Kimura G. Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Nephrol Dial Transplant 2002;17:916-22.
14. 12 for the treatment of hyperhomocysteinaemia in dialysis patients. Intern Med J 2003;33:489-94.
15. 12 on total plasma homocysteine concentration in folate-replete hemodialysis patients. Clin Nephrol 2003;59:186-9.
16. 12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Metabolism 2003;52:168-72.
17. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism 1999;48: 631-5.
18. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drueke T, Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999;56:2292-6.
19. 12 and folate. Res Exp Med (Berl) 2001;200:155-68.
20. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Elevation of 2-methylcitric acid I and II levels in serum, urine, and cerebrospinal fluid of patients with cobalamin deficiency. Metabolism 1993;42:978-88.
21. Stabler SP, Lindenbaum J, Savage DG, Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993;81:3404-13.
22. Snavely J. Hyperhomocysteinemia in end stage renal disease: is treatment necessary? Nephrol Nurs J 2002;29:155-60.
23. Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis 2001;38(4 Suppl 1):91-4.
24. Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr 2004;14:64-71.
25. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002;50:1789-95.
26. Moelby L, Rasmussen K, Ring T, Nielsen G. Relationship between methylmalonic acid and cobalamin in uremia. Kidney Int 2000;57:265-73.
27. Allen RH, Stabler SP, Lindenbaum J. Relevance of vitamins, homocysteine and other metabolites in neuropsychiatric disorders. Eur J Pediatr 1998;157(Suppl 2):122-6.
28. Scott JM, Weir DG. The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic-acid induced exacerbation of subacute combined degeneration in pernicious anaemia. Lancet 1981;2:337-40.
29. Markle HV. Cobalamin. Crit Rev Clin Lab Sci 1996;33:247-56.
30. Herbert V. Staging vitamin B-12 (cobalamin) status in vegetarians. Am J Clin Nutr 1994;59(Suppl 5):1213-22.
31. Obeid R, Kuhlmann M, Kirsch KM, Herrmann W. Cellular uptake of vitamin B12 in patients with chronic renal failure. Nephron; in press.
32. Henning BF, Riezler R, Tepel M, Langer K, Raidt H, Graefe U, Zidek W. Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 1999;83:314-22.
33. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996;98:177-84.
34. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-6.
35. Fabbian F, Catalano C, Bordin V, Balbi T, Di Landro D. Esophagogastroduodenoscopy in chronic hemodialysis patients: 2-year clinical experience in a renal unit. Clin Nephrol 2002;58:54-9.